March 15, 2019 - 8:04 PM EDT
Apellis Pharmaceuticals Presses On With Late-Stage Studies After Trial Enrollment Pause

Apellis Pharmaceuticals Presses On With Late-Stage Studies After Trial Enrollment Pause

Apellis Pharmaceuticals (APLS) recently announced that it was allowed to resume enrollment into its clinical trials dealing with geographic atrophy ((GA)). GA, in essence, is advanced age-related macular degeneration ((AMD)) or advanced dry AMD. The trial was halted back in October of 2018, because treatment with APL-2 caused noninfectious inflammation. However, at that time, the company noted that the likely cause was found and said it would be able to resume the trial in the following months. The ability to recruit in both phase 3 studies for APL-2 is well underway again, and

Read more ...


Source: SeekingAlpha (March 15, 2019 - 8:04 PM EDT)